View the research:
A Cost-Effectiveness Analysis Using Real-World Data from the MSBase Registry: Comparing Natalizumab to Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy. Herring WL, Gould IG, Casamassima G, Santoni L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H
A Cost-Effectiveness Analysis Using Real-World Data from the MSBase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain. Herring WL, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H
Multiple sclerosis, or MS, is a progressive, disabling neurological disease associated with a significant humanistic and economic burden. While there is no cure for MS, disease-modifying therapies have been shown to have an impact on MS-related disability and relapses.
Using real-world data from the international MSBase registry we studied the clinical effectiveness of switching to natalizumab for patients with relapsing-remitting MS who are not responding to established first-line therapies. We combined these results with survey data on the burden of MS in European countries to develop cost-effectiveness models comparing natalizumab with fingolimod in Italy and Spain.
In the MSBase analysis, natalizumab led to a significant reduction in relapse rates and an increase in the rate of disability improvement. In the cost-effectiveness analyses for both Italy and Spain, these clinical benefits translated to higher quality-adjusted life-years and lower costs for natalizumab compared with fingolimod.
In addition to supporting the cost-effectiveness of natalizumab as a disease-modifying therapy for relapsing-remitting MS, this research represents an important step forward as the first study to use real-world effectiveness data in an economic evaluation for MS.
Learn more about how RTI Health Solutions can assist you in analyzing and communicating your product's cost-effectiveness.